INNV-25. ASSESSING SLEEP AND CIRCADIAN RHYTHMS IN PRIMARY BRAIN TUMORS PATIENTS: AN OBSERVATIONAL STUDY. (14th November 2022)
- Record Type:
- Journal Article
- Title:
- INNV-25. ASSESSING SLEEP AND CIRCADIAN RHYTHMS IN PRIMARY BRAIN TUMORS PATIENTS: AN OBSERVATIONAL STUDY. (14th November 2022)
- Main Title:
- INNV-25. ASSESSING SLEEP AND CIRCADIAN RHYTHMS IN PRIMARY BRAIN TUMORS PATIENTS: AN OBSERVATIONAL STUDY
- Authors:
- Wollet, Alex
Leeper, Heather
Vera, Elizabeth
Mentges, Kelly
King, Amanda
Rogers, James
Sass, Dilorom (Delia)
Acquaye, Alvina
Adegbesan, Kendra
Boris, Lisa
Burton, Eric
Celiku, Orieta
Chambers, Claudia
Choi, Anna
Christ, Alexa
De Le Minyety, Julianie Cruz
Evans, Karen
Grajkowska, Ewa
Komlodi-Pasztor, Edina
Levine, Jason
Lindsley, Matthew
Lollo, Nicole
Mendoza, Tito
Miller, Hope
Panzer, Marissa
Penas-Prado, Marta
Pillai, Valentina
Polskin, Lily
Reyes, Jennifer
Roche, Kayla
Sahebjam, Solmaz
Stockdill, Macy
Theeler, Brett
Wall, Kathleen
Wu, Jing
Gilbert, Mark
Armstrong, Terri
Shuboni-Mulligan, Dorela
… (more) - Abstract:
- Abstract: Sleep-wake disturbances are among the most common and severe symptoms in primary brain tumor (PBT) patients. Currently, no studies have quantified their physiological sleep measurements or compared these assessments to established patient reported outcome measures (PROs). Smart wearable devices, such as Fitbits, continuously monitor patient behaviors at home and provide detailed physiological measurements of sleep, activity, and heart rate. We hypothesized that smart wearable devices can accurately determine physiological sleep disturbances and circadian disruptions and will complement established PROs in a PBT patient population. This observational, cross-sectional trial monitors sleep and circadian rhythm variables using Fitbit smart wearable devices worn for 1 month. Additionally, participants will answer PROs questionnaires (PROMIS Sleep Disturbance and Sleep Related Impairment-Short Forms, Sleep Hygiene Index, Morningness-Eveningness questionnaire, and Consensus Sleep Diary) at study entry and during the last week on-study. The present study is a planned interim analysis of 54 patients to assess feasibility, including evaluation of enrollment, attrition, study parameter completion and data missingness. 73 PBT patients were screened and approached. Of these patients, 54 (74%) were enrolled on study and 19 (26%) declined participation (8 lacked interest, 3 discomfort wearing watches, 3 lacked smart phone, 2 unable to wear device at work, 2 unable to attendAbstract: Sleep-wake disturbances are among the most common and severe symptoms in primary brain tumor (PBT) patients. Currently, no studies have quantified their physiological sleep measurements or compared these assessments to established patient reported outcome measures (PROs). Smart wearable devices, such as Fitbits, continuously monitor patient behaviors at home and provide detailed physiological measurements of sleep, activity, and heart rate. We hypothesized that smart wearable devices can accurately determine physiological sleep disturbances and circadian disruptions and will complement established PROs in a PBT patient population. This observational, cross-sectional trial monitors sleep and circadian rhythm variables using Fitbit smart wearable devices worn for 1 month. Additionally, participants will answer PROs questionnaires (PROMIS Sleep Disturbance and Sleep Related Impairment-Short Forms, Sleep Hygiene Index, Morningness-Eveningness questionnaire, and Consensus Sleep Diary) at study entry and during the last week on-study. The present study is a planned interim analysis of 54 patients to assess feasibility, including evaluation of enrollment, attrition, study parameter completion and data missingness. 73 PBT patients were screened and approached. Of these patients, 54 (74%) were enrolled on study and 19 (26%) declined participation (8 lacked interest, 3 discomfort wearing watches, 3 lacked smart phone, 2 unable to wear device at work, 2 unable to attend consent calls, 1 pregnancy and 1 cognitive complication). The accrued patients were 56% male, 56% ³ 50 years of age, and 81% had a KPS ³ 90. Patients represented different stages of treatment: 6% of patients were newly diagnosed, 24% on active treatment (11% 1 st recurrence, 13% 2 nd recurrence), and 70% were on imaging surveillance. Feasibility was confirmed as there were no deviations reported and 100% of PROs and study timepoints completed. Quantified Fitbit data including percent time worn and physiologic sleep parameters will be reported. Study enrollment for efficacy measures continues. … (more)
- Is Part Of:
- Neuro-oncology. Volume 24(2022)Supplement 7
- Journal:
- Neuro-oncology
- Issue:
- Volume 24(2022)Supplement 7
- Issue Display:
- Volume 24, Issue 7 (2022)
- Year:
- 2022
- Volume:
- 24
- Issue:
- 7
- Issue Sort Value:
- 2022-0024-0007-0000
- Page Start:
- vii146
- Page End:
- vii147
- Publication Date:
- 2022-11-14
- Subjects:
- Brain Neoplasms -- Periodicals
Brain -- Tumors -- Periodicals
Brain -- Cancer -- Periodicals
Nervous system -- Cancer -- Periodicals
616.99481 - Journal URLs:
- http://neuro-oncology.dukejournals.org/ ↗
http://neuro-oncology.oxfordjournals.org/ ↗
http://www.oxfordjournals.org/content?genre=journal&issn=1522-8517 ↗
http://ukcatalogue.oup.com/ ↗ - DOI:
- 10.1093/neuonc/noac209.565 ↗
- Languages:
- English
- ISSNs:
- 1522-8517
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6081.288000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 24937.xml